Drug approvals: '08 in review. Nebivolol (Bystolic).
作者信息
Laustsen Gary, Carrillo Fernando, Johnson Jessica, Smith Cynthia
机构信息
Oregon Health and Science University, Portland, Ore., USA.
出版信息
Nurse Pract. 2009 Feb;34(2):25-6. doi: 10.1097/01.NPR.0000345266.90547.be.
Abstract
摘要
相似文献
1
Drug approvals: '08 in review. Nebivolol (Bystolic).
Nurse Pract. 2009 Feb;34(2):25-6. doi: 10.1097/01.NPR.0000345266.90547.be.
2
Nebivolol (Bystolic) for hypertension.
Med Lett Drugs Ther. 2008 Mar 10;50(1281):17-9.
3
[Hemodynamic properties of nebivolol].
Cardiologia. 1999 Dec;44 Suppl 1(Pt 1):369-72.
4
Beta-blockers in the management of hypertension: focus on nebivolol.
Expert Rev Cardiovasc Ther. 2008 Apr;6(4):471-9. doi: 10.1586/14779072.6.4.471.
5
[Clinical pharmacology of nebivolol].
Cardiologia. 1999 Dec;44 Suppl 1(Pt 1):361-4.
6
[Therapeutic effects of nebivolol].
Cardiologia. 1999 Dec;44 Suppl 1(Pt 1):365-8.
7
Metabolic effects of beta-blockers: importance of dissociating newer from conventional agents.
J Hypertens. 2007 Jan;25(1):249-52; author reply 252-3. doi: 10.1097/HJH.0b013e3280104fa5.
8
[Pharmacological modulation of NO synthesis in patients with arterial hypertension and endothelial dysfunction].
Klin Med (Mosk). 2003;81(7):51-5.
9
[Beta-1 blockade plus NO release. Additional organ protection for patients with hypertension].
MMW Fortschr Med. 2003 Oct 2;145(40):57.
10
[Beta blocker improves the endothelial function. Gas-forming blood vessel protection].
MMW Fortschr Med. 2003 Dec 18;145(51-52):41.
Zotero 插件